This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kanetsky, P. A. Articles by Rebbeck, T. R. Search for Related Content PubMed PubMed Citation Articles by Kanetsky, P. A. Articles by Rebbeck, T. R.

Interaction of Glutathione S-Transferase M1 and T1 Genotypes and Malignant Melanoma¹

Departments of Biostatistics and Epidemiology [P. A. K., R. H., A. W., D. N., J. S., T. R. R.] and Medicine, Division of Hematology-Oncology [D. G.], University of Pennsylvania, Philadelphia, Pennsylvania 19104, and Department of Dermatology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021 [A. H.]

	Abstract

Top Abstract Introduction Materials and Methods Discussion References

 
The µ and classes of glutathione S-transferases (GST) may affect the development of cutaneous malignant melanoma (CMM) by decreasing cellular oxidative stress in skin. These isozymes are absent in a large proportion of the population because of germ-line homozygous deletions in the genes encoding GSTM1 and GSTT1. To determine the association between GSTM1 and GSTT1 homozygous deletions (GSTM1 null and GSTT1 null, respectively) and CMM, we studied 212 patients with CMM, 150 patients with CMM and dysplastic nevi (DN), 147 patients with DN alone, and 124 healthy persons without CMM or DN. Comparing CMM cases (n = 362) to participants without CMM (n = 271), we found no association with GSTM1 null [odds ratio (OR), 1.2; 95% confidence interval (CI), 0.86–1.6] or GSTT1 null (OR, 0.82; 95% CI, 0.56–1.2), either independently or in combination (OR, 1.4; 95% CI, 0.81–2.2), after adjusting for age. However, among the subset of participants with red or blond hair, those with CMM were twice as likely to carry GSTM1 null (OR, 2.2; 95% CI, 1.2–4.2) and nearly 10-fold more likely to carry both GSTM1 null and GSTT1 null (OR, 9.5; 95% CI, 1.2–73) compared with those without CMM. These data suggest that among persons with hair colors traditionally associated with increased risk for melanoma, absence of both GSTM1 and GSTT1 may act to further elevate CMM risk.

	Introduction

Top Abstract Introduction Materials and Methods Discussion References

 
Increased levels of cellular oxidative stress can be harmful to the faithful replication of DNA. Oxidative stress resulting in lipid peroxidation and DNA hydroperoxide formation can be induced in skin by UV radiation (1) . Because one function of GST³ is the reduction of these potential mutagens (2 , 3) , GST isozymes active in skin, including GSTM1 and GSTT1, may play a role in protection against development of cutaneous neoplasms, including CMM. Polymorphisms in members of the GST family have been shown to influence risk of cancers at several sites, including nonmelanoma skin cancers (4) and multiple cutaneous skin cancers (4, 5, 6) . Lafuente et al. (7) measured leukocytic GSTM1 levels by enzyme-linked immunoassay and noted that CMM patients were twice as likely to have decreased levels of GSTM1 compared with controls. Two other studies (4 , 8) genotyped GSTM1 using PCR and reported no significant difference in the proportion of those homozygous for the GSTM1 deletion (GSTM1 null) between CMM patients and controls. One additional study (9) published in abstract form only reported a significant association between CMM and carriage of the GSTT1 homozygous deletion (GSTT1 null) but not GSTM1 null. DN are atypical moles that are epidemiological risk markers of CMM and nonobligate precursors (10) . Their association with GST status has not been reported.

To gain additional insight into the complex etiology of CMM, we designed a case-control study to evaluate the associations among GSTM1 and GSTT1, pigmentation characteristics, DN, and CMM.

	Materials and Methods

Top Abstract Introduction Materials and Methods Discussion References

 
Setting and Population
Participants in the present study were accrued into a case-control study at the Pigmented Lesion Clinic of the Hospital of the University of Pennsylvania between September 1997 and September 1999. The Institutional Review Board of the University of Pennsylvania that oversees research involving human beings approved this study, and informed consent was obtained from each participant. Any clinic patient with incident CMM, defined as CMM histologically diagnosed within a year of their clinic visit, was eligible to participate. Patients with a first-time clinical diagnosis of DN (within 1 year of their clinic visit) were also eligible to participate. Patients who had a clinical or histological diagnosis of DN 1 year or more before the date of their study participation were excluded from study. We did not select patients based on prior knowledge of family history of melanoma or other melanoma risk factors, and those with more that one primary CMM were not eligible to participate regardless of the date of their first CMM. For each clinic patient enrolled, we asked for the name of a healthy nonblood relative or acquaintance to contact as a potential control subject.

Data Collection and Measurement
Information on pigmentation characteristics and sun exposure history was obtained from a brief self-administered questionnaire. We asked about natural hair color as a teenager, natural eye color, initial skin reaction after exposure to the first strong sunlight of summer, skin reaction after long and repeated sun exposure, and freckling on the face and upper back. One research nurse (R. H.) completed a full skin examination, excluding the scalp and genitalia, for all of the study participants, and the following information was recorded: total mole count, total number of large moles (>8 mm), number of DN, and presence or absence of freckling. A buccal sample was self-collected by each study participant using sterile cheek swabs (Cyto-Pak Cytosoft Brush; Medical Packaging Corporation, Camarillo, CA) to collect a germ-line DNA sample.

GSTM1 and GSTT1 Genotyping
Genomic DNA from the buccal swab was extracted using the protocol of Walker et al. (11) , and the complete gene deletion at GSTT1 and GSTM1 was determined by using PCR-based assays modified from the protocol of Rebbeck et al. (12) . The modified protocol used exon 4 of the sulfotransferase (SULT1E1) gene to serve as a positive internal control for the amplification of GSTM1 rather than the ß-globin-positive internal control reported previously. These primers were SULT exon 4 forward, 5' TGG AGT TGC TTA ACC TTT ACT-3'; and SULT exon 4 reverse, 5' GAG AAC ACT TGA CTC TGG TTA C 3'. We did not distinguish the homozygous active from the heterozygous active genotype for either GSTM1 or GSTT1.

Data Coding
Case Status.
We grouped participants according to the presence or absence of CMM. The CMM case group included patients with CMM alone and those with both CMM and DN. The control group included patients with DN alone and healthy participants without CMM or DN.

GST Genotypes.
We dichotomized GST genotypes based on the presence of at least one active allele. "GSTM1 active" indicates the presence of at least one nondeleted GSTM1 allele, whereas "GSTM1 null" indicates the presence of two deleted GSTM1 alleles. Similarly, "GSTT1 active" indicates the presence of at least one nondeleted GSTT1 allele, and "GSTT1 null" indicates the presence of two deleted GSTT1 alleles. A composite GST genotype was created to reflect overall GST activity. "GST active " indicates the presence of at least one nondeleted active allele in either GSTM1 or GSTT1, whereas "GST null " indicates both GSTM1 null and GSTT1 null.

Nevi Outcomes.
We categorized the total number of DN and the total number of large nevi as 0, 1, 2–5, 6–9, and 10 or more. All of the classes of nevi, including banal nevi, DN, and congenital nevi, were included in the count of large nevi. Total number of nondysplastic nevi was categorized as 1–24, 25–49, 50–74, and 75 or more and includes counts of large and small (8 mm) banal nevi and congenital nevi.

Pigmentation Characteristics.
Questionnaire information on hair color was coded as red (including reddish-brown), blond, or dark (including light brown, medium brown, dark brown, gray, and black); on eye color as blue or gray, green or hazel, or dark (including light brown, dark brown, and black); on freckling as many, few, or none; on skin reaction to acute sun as burn and blister, burn without blister, or tan (including mild sunburn followed by a tan, no sunburn and no tan, tan with no sunburn, and no change in skin color); and on skin reaction to chronic sun as no tan, light tan, or medium to dark tan.

Statistical Analysis
Median counts of nevi outcomes were compared nonparametrically using Mann-Whitney U Wilcoxon rank-sum tests. Using unconditional logistic regression models, we calculated age-adjusted ORs and 95% CIs for associations between pigmentation characteristics and CMM, freckling and nevi types and GST genotype, and GST genotype and CMM. For each model, independent variables were entered as (0,1) indicator variables, where 1 specified the presence of the variable and 0 specified the absence of the variable. Independent variables with more than two levels were considered as ordinal variables to test for linear trend. For all of the analyses of pigmentation characteristics and CMM, total number of DN was additionally adjusted for in the logistic model.

To evaluate effect modification, we determined ageadjusted ORs and 95% CIs of CMM within pigmentation categories. Because the stratum-specific number of subjects for some pigmentation characteristics was too small to support subgroup analysis, we combined categories to create dichotomous variables (hair color: red, reddish-brown, blond versus light brown, medium brown, dark brown, gray, and black; eye color: blue, gray, green, hazel versus light brown, dark brown, and black; freckling: any versus none; skin reaction to acute sun: burn without tanning, regardless of blistering versus tanning or no effect, regardless of burning; and skin reaction to chronic sun: no or light tan versus medium or dark tan). We chose to combine the moderate and high risk categories and keep separate the low risk category in an attempt to highlight subgroups that identify persons at reduced risk of melanoma and persons at some increased risk of melanoma.

Results
Our study sample included 362 CMM cases and 271 controls without CMM. All of the participants were Caucasian, and only five (two CMM cases and three controls) reported being of Hispanic origin. The gender distribution was similar among those with CMM (50% male) and those without (53% male; ² = 1.02; P = 0.31). The mean age of CMM cases (50.6 ± 14.0) was statistically significantly older than that of controls without CMM (45.1 ± 13.4; P = 0.0001). No difference in ever-smoking was noted between the groups (² = 0.28; P = 0.60).

Association of Pigmentation Characteristics and CMM.
Adjusted ORs for CMM in relation to self-reported pigmentation characteristics are given in Table 1 . The strongest predictors of CMM were freckling and skin reaction to chronic sun exposure. CMM cases were nearly four times as likely to report many freckles (OR, 3.7; 95% CI, 2.4–5.8) and nearly two times as likely to report few freckles (OR, 1.9; 95% CI, 1.3–2.9) compared with controls. Compared with controls, CMM cases were over twice as likely to report both an inability to tan (OR, 2.6; 95% CI, 1.2–5.6) and a light tanning ability (OR, 2.1; 95% CI 1.5–3.1) in response to chronic sun. A statistically significant linear trend was observed for these associations. Patients with CMM were over four times as likely to be redheaded (OR, 4.6; 95% CI, 2.1–10.2) compared with controls without CMM. Blond hair was not predictive of CMM (OR, 1.3; 95% CI, 0.85–1.9).

Association of Cutaneous Markers of CMM Risk and GST Genotype.
Comparing participants who were GST null (n = 78) to those who were GST active (n = 555), there were no statistically significant differences in the median number of total nevi (32.5; IQR, 8–74; and 24; IQR, 8–66, respectively) or median number of DN (1; IQR, 0–6; and 0; IQR, 0–3, respectively). Results were similar comparing median nevus counts across GSTM1 and GSTT1 status (data not shown). Table 2 shows age-adjusted ORs for associations of nondysplastic nevi, DN, and freckling with GST genotype. Persons with 10 or more DN were nearly three times as likely (OR, 2.8; 95% CI, 1.4–5.6) to be GST null. The linear trend for increasing categories of DN count did not reach significance at the = 0.05 level. There was no association of reported freckling and GST genotypes.

	Discussion

Top Abstract Introduction Materials and Methods Discussion References

A biological interaction between GST genotype and hair color is quite plausible. Persons with lighter hair color, i.e., red and blond hair, tend to have fairer skin complexion and a corresponding greater proportion of pheomelanin in the epidermis (13) . This is in contrast to those with brown or black hair who tend to have darker skin complexion and a greater amount of eumelanin. Pheomelanin is a poorer protector against cellular oxidative stress than is eumelanin because reactive oxygen species may be more likely to form when pheomelanin is exposed to UV radiation (14) .

Our data support a moderate yet significant association with GSTM1 null and CMM among persons with light (i.e., red, reddish-brown, and blond) hair color. It is possible that GSTM1 is a more efficient reducer of oxidized DNA and lipids than GSTT1 in skin. It is clear, however, that the combination of GSTM1 null and GSTT1 null confers the greatest risk of CMM in light-haired individuals. The association between GST null and CMM among persons with light hair color remained statistically significant even after further adjustment for either total number of DN alone or in combination with all of the other pigmentation characteristic variables included in Table 4 (data not shown). Because GSTM1 and GSTT1 have complementary yet somewhat redundant biochemical properties, the absence of an active form of both isozymes may represent a more limited ability to reduce cellular oxidative stress. Kerb et al. (15) noted that the minimal erythematous dose of UVB irradiation was lowest among three healthy subjects who were both GSTM1 null and GSTT1 null.

We acknowledge that our ability to draw strong conclusions based on these data is limited because of the small number of persons who were GST null and the potential for spurious associations resulting from the number of tests of significance performed.

We speculate that the association between GST null and CMM would be even greater among a subgroup consisting of only redheads. We were unable to directly test this in our data. The number of redheads in our study population totaled 51, of whom only 5 were controls and only 3 had DN. None of these redheaded controls were genotyped as GST null. In fact, only one subject without CMM (who was blond) was GST null, which contributed to the imprecision of the parameter estimate.

Of interest was the lack of a clear association between GST genotypes and measures of cutaneous risk markers for CMM, specifically DN. Because some, but not all, CMM arise from DN precursors, it may be that GSTM1 null and GSTT1 null play a more crucial role in later stage melanocytic carcinogenesis by contributing to the continued deregulation of cellular functions within an already functionally and morphologically abnormal DN.

Seemingly inconsistent was the moderate association between GST null and floridly expressed (10 or more) DN. Because these persons are at greatest risk for development of CMM (10) , it is possible that this association is indicative of an undiagnosed CMM rather than increased number of DN per se. To determine whether the lack of association between GST null and DN count was, in part, determined by the presence of CMM, we repeated analyses after stratification on case-control status. The Cochran-Mantel-Haenszel statistic (17.5; P = 0.002) indicated that the association of GST null and DN was the same in cases and controls. However, we did note an increased likelihood of GST null (OR, 2.0; 95% CI, 0.92–4.5) among CMM cases with a solitary DN, compared with a decreased likelihood of GST null (OR, 0.29; 95% CI, 0.04–2.3) among controls with a solitary DN.

We have extensively evaluated our control group to better understand the potential impact of our sampling design on our reported associations. The majority of controls were partners of clinic patients (87%), 10% were friends, and 3% were in-laws or adoptive relatives. Statistical tests did not reveal any difference between partner controls and friend controls for either pigmentation characteristic or GST genotyping results (data not shown). The prevalence of GSTM1 null in CMM-free controls (46%) was well within the range published for this null polymorphism, whereas the prevalence of GSTT1 null among this group (24%) was slightly higher than that previously reported in Caucasians (reviewed in Ref. 16 ). Comparing DN controls with referred healthy controls without DN or CMM, there were no statistically significant differences in the proportions with GSTM1 null (² = 0.84; P = 0.36), GSTT1 null (² = 1.9; P = 0.17), or GST null (² = 0.01; P = 0.92).

It is possible that a shared etiology exists between DN and CMM. Under this assumption, bias introduced by including DN into the referent group would likely make it more difficult to detect significant associations. Reassuringly, the associations we found between CMM and pigmentation characteristics were similar to those published previously (reviewed in Ref. 17 ).

Additional evaluation will be required to further explore the apparent interaction between GST genotypes and hair color phenotype (18) and to relate these results to additional factors determining melanogenesis and melanocytic carcinogenesis, e.g., melanocortin-1 receptor allelic variation (18, 19, 20) . Phenotypic pigmentation alone is not sufficient to predict CMM risk. The additional information provided by genotyping may contribute significantly to better models of prediction, prevention, and treatment of CMM.

	Acknowledgments

 
We thank the past and present physicians of the Pigmented Lesion Clinic, Drs. David Elder, Rosalie Elenitsas, Stuart Lessin, Lynn Schuchter, and Jonathan Wolfe, without whom this study would not have been a possibility. We thank Marie Synnestvedt for her support with data management and manipulation. Finally, we thank Cheryl Doyle for her continued help in bridging the gap between clinical care and research protocol and Dr. Anne Deitz for her laboratory contributions.

	Footnotes

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported by NIH Grant P01 CA75434-01.

² To whom requests for reprints should be addressed, at Department of Biostatistics and Epidemiology, 908 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021. Phone: (215) 573-3282; Fax: (215) 573-2265; E-mail: pkanetsk{at}cceb.med.upenn.edu

³ The abbreviations used are: GST, glutathione S-transferase; CI, confidence interval; CMM, cutaneous malignant melanoma; DN, dysplastic nevi; IQR, interquartile range; OR, odds ratio; SULT, sulfotransferase.

Received 12/ 1/00; revised 2/15/01; accepted 2/22/01.

	References

Top Abstract Introduction Materials and Methods Discussion References

 

1. Griffiths H. R., Mistry P., Herbert K. E., Lunec J. Molecular and cellular effect of ultraviolet light-induced genotoxicity. Crit. Rev. Clin. Lab. Sci., 35: 189-237, 1998.[Medline]
2. Ketterer B., Meyer D. J. Glutathione transferases: a possible role in the detoxication and repair of DNA and lipid hydroperoxides. Mutat. Res., 214: 33-40, 1989.[Medline]
3. Wang W., Ballatori N. Endogenous glutathione conjugates: occurrence and biological functions. Pharmacol. Rev., 50: 335-355, 1998.[Abstract/Free Full Text]
4. Heagerty A. H. M., Fitzgerald D., Smith A., Bowers B., Jones P., Fryer A. A., Zhao L., Alldersea J., Strange R. C. Glutathione S-transferase GSTM1 phenotypes and protection against cutaneous tumors. Lancet, 343: 266-268, 1994.[Medline]
5. Heagerty A., Smith A., English J., Lear J., Perkins W., Bowers B., Jones P., Gilford J., Alldersea J., Fryer A., Strange R. C. Susceptibility to multiple cutaneous basal cell carcinomas: significant interaction between glutathione S-transferase GSTM1 genotypes, skin type, and male gender. Br. J. Cancer, 73: 44-48, 1996.[Medline]
6. Lear J. T., Heagerty A. H. M., Smith A., Bowers B., Payne C. R., Smith C. A. D., Jones P. W., Gilford J., Yengi L., Alldersea J., Fryer A. A., Strange R. C. Multiple cutaneous basal cell carcinomas: glutathione S-transferase (GSTM1, GSTT1) and cytochrome P450 (CYP2D6, CYP1A1) polymorphisms influence tumour numbers and accrual. Carcinogenesis (Lond.), 17: 1891-1896, 1996.[Abstract/Free Full Text]
7. Lafuente A., Molina R., Palou J., Castel T., Moral A., Trias M. Phenotype of glutathione S-transferase µ (GSTM1) and susceptibility to malignant melanoma. Br. J. Cancer, 72: 324-326, 1995.[Medline]
8. Shanley S. M., Chenevix-Trench G., Palmer J., Hayward N. Glutathione S-transferase GSTM1 null genotype is not over-represented in Australian patients with nevoid basal cell carcinoma syndrome or sporadic melanoma. Carcinogenesis (Lond.), 16: 2003-2004, 1995.[Abstract/Free Full Text]
9. Lee J. E., Cheng L., Mansfield P. F., Ross M. I., Gershenwald J. E., Char D., Chen M., Lu M., Wei Q. GSTT1 and GSTM1 polymorphisms and risk of melanoma. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 18: 540a 1999.
10. Tucker M. A., Halpern A., Holly E. A., Hartge P., Elder D. E., Sagebiel R. W., Guerry D., IV, Clark W. H., Jr. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA, 277: 1439-1444, 1997.[Abstract]
11. Walker A. H., Najarian D., White D. L., Jaffe J. M., Kanetsky P. A., Rebbeck T. R. Collection of genomic DNA by buccal swabs for polymerase chain reaction-based biomarker assays. Environ. Health Perspect., 107: 3-7, 1999.[Medline]
12. Rebbeck T. R., Walker A. H., Jaffe J. M., White D. L., Wein A. J., Malkowicz S. B. Glutathione S-transferase-µ (GSTM1), and - (GSTT1) genotypes in the etiology of prostate cancer. Cancer Epidemiol. Biomark. Prev., 8: 283-287, 1999.[Abstract/Free Full Text]
13. Hunt G., Kyne S., Ito S., Wakamatsu K., Todd C., Thody A. Eumelanin and pheomelanin contents of human epidermis and cultured melanocytes. Pigm. Cell Res., 8: 202-208, 1995.[Medline]
14. Menon I. A., Persad S., Ranadive N. S., Haberman H. F. Photobiological effects of eumelanin and pheomelanin Bagnara J. Klaus S. N. Paul E. Schartl M. eds. . Biological, Molecular, and Clinical Aspects of Pigmentation, : 77-85, University of Tokyo Press Tokyo 1985.
15. Kerb R., Brockmoller J., Reum T., Roots I. Deficiency of glutathione S-transferases T1 and M1 as heritable factors of increased cutaneous UV sensitivity. J. Investig. Dermatol., 108: 229-232, 1997.[Medline]
16. Rebbeck T. R. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol. Biomark. Prev., 6: 733-743, 1997.[Abstract]
17. Bliss J. M., Ford D., Swerdlow A. J., Armstrong B. K., Cristofolini M., Elwood J. M., Green A., Holly E. A., Mack T., MacKie R. M., Østerlind A., Walter S. D., Peto J., Easton D. F. Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. Int. J. Cancer, 62: 367-376, 1995.[Medline]
18. Strange R. C., Ellison T., Ichii-Jones F., Bath J., Hoban P., Lear J. T., Smith A. G., Hutchinson P. E., Osborne J., Bowers B., Jones P. W., Fryer A. A. Cytochrome P450 CYP2D6 genotypes: association with hair color, Breslow thickness, and melanocyte stimulating hormone receptor alleles in patients with malignant melanoma. Pharmacogenetics, 9: 269-276, 1999.[Medline]
19. Valverde P., Healy E., Jackson I., Rees J. L., Thody A. J. Variants of the melanocyte stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat. Genet., 11: 328-330, 1995.[Medline]
20. Palmer J. S., Duffy D. L., Box N. F., Aitken J. F., O’Gorman L. E., Green A. C., Hayward N. K., Martin N. G., Sturm R. A. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype?. Am. J. Hum. Genet., 66: 176-186, 2000.[Medline]

This article has been cited by other articles:

				J. M. Marzec, J. D. Christie, S. P. Reddy, A. E. Jedlicka, H. Vuong, P. N. Lanken, R. Aplenc, T. Yamamoto, M. Yamamoto, H.-Y. Cho, et al. Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury FASEB J, July 1, 2007; 21(9): 2237 - 2246. [Abstract] [Full Text] [PDF]

				N. Soufir, R. Meziani, J.-J. Lacapere, G. Bertrand, F. Fumeron, A. Bourillon, B. Gerard, V. Descamps, B. Crickx, L. Ollivaud, et al. Association Between Endothelin Receptor B Nonsynonymous Variants and Melanoma Risk J Natl Cancer Inst, September 7, 2005; 97(17): 1297 - 1301. [Abstract] [Full Text] [PDF]

				S. Jackson, M. Harland, F. Turner, C. Taylor, P. A. Chambers, J. Randerson-Moor, A. J. Swerdlow, I. dos Santos Silva, S. Beswick, D. T. Bishop, et al. No Evidence for BRAF as a Melanoma/Nevus Susceptibility Gene Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 913 - 918. [Abstract] [Full Text] [PDF]

				P. A. Kanetsky, F. Ge, D. Najarian, J. Swoyer, S. Panossian, L. Schuchter, R. Holmes, D. Guerry, and T. R. Rebbeck Assessment of Polymorphic Variants in the Melanocortin-1 Receptor Gene with Cutaneous Pigmentation Using an Evolutionary Approach Cancer Epidemiol. Biomarkers Prev., May 1, 2004; 13(5): 808 - 819. [Abstract] [Full Text] [PDF]

				E Matichard, P Verpillat, R Meziani, B Gerard, V Descamps, E Legroux, M Burnouf, G Bertrand, F Bouscarat, A Archimbaud, et al. Melanocortin 1 receptor (MC1R) gene variants may increase the risk of melanoma in France independently of clinical risk factors and UV exposure J. Med. Genet., February 1, 2004; 41(2): e13 - 13. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kanetsky, P. A. Articles by Rebbeck, T. R. Search for Related Content PubMed PubMed Citation Articles by Kanetsky, P. A. Articles by Rebbeck, T. R.